Actively Recruiting
Phase III Study of Proton-Spatially Fractionated Radiotherapy with Standard Radiation and Surgery for New Retroperitoneal Soft Tissue Sarcoma
Led by Northwestern University · Updated on 2026-07-07
28
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a new type of radiation therapy called proton-spatially fractionated radiotherapy P-SFRT for patients with newly diagnosed retroperitoneal soft tissue sarcoma, a type of cancer. This phase III trial aims to find the best dose of P-SFRT and to evaluate how well it works in combination with standard radiation therapy and surgery. The trial also looks at safety and effectiveness outcomes such as tumor response and patient survival. Participants receive P-SFRT in a single treatment session, followed by standard image-guided intensity modulated radiation therapy IG-IMRT over 25 to 28 treatment sessions lasting 35 to 42 days. After radiation treatments, patients undergo surgical removal of the tumor 21 to 35 days later. The study includes sample collections such as blood draws and biopsies during screening and treatment, as well as CT scans during the study and follow-up periods. During the trial, participants are closely monitored with blood tests, imaging, and biopsies. Follow-up visits occur at 30 and 90 days after surgery and continue for up to 36 months to track safety and treatment outcomes. The main measures include determining the recommended dose of P-SFRT, evaluating tumor response, progression-free survival, and overall survival over this time frame.
CONDITIONS
Brief Title
Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma
Research Team
S
Study Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here